|
1
|
Louis DN, Ohgaki H, Wiestler OD, et al:
The 2007 WHO classification of tumours of the central nervous
system. Acta Neuropathol. 114:97–109. 2007.
|
|
2
|
Ohgaki H, Dessen P, Jourde B, et al:
Genetic pathways to glioblastoma: a population-based study. Cancer
Res. 64:6892–6899. 2004.
|
|
3
|
Cancer Genome Atlas Research Network.
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008.
|
|
4
|
Ohgaki H and Kleihues P: Genetic
alterations and signaling pathways in the evolution of gliomas.
Cancer Sci. 100:2235–2241. 2009.
|
|
5
|
Lee JJ, Kim BC, Park MJ, et al: PTEN
status switches cell fate between premature senescence and
apoptosis in glioma exposed to ionizing radiation. Cell Death
Differ. 18:666–677. 2011.
|
|
6
|
Quick QA and Gewirtz DA: An accelerated
senescence response to radiation in wild-type p53 glioblastoma
multiforme cells. J Neurosurg. 105:111–118. 2006.
|
|
7
|
Nam HY, Han MW, Chang HW, et al:
Radioresistant cancer cells can be conditioned to enter senescence
by mTOR inhibition. Cancer Res. 73:4267–4277. 2013.
|
|
8
|
Hwang ES, Yoon G and Kang HT: A
comparative analysis of the cell biology of senescence and aging.
Cell Mol Life Sci. 66:2503–2524. 2009.
|
|
9
|
Chowdhury M, Mihara K, Yasunaga S, Ohtaki
M, Takihara Y and Kimura A: Expression of Polycomb-group (PcG)
protein BMI-1 predicts prognosis in patients with acute myeloid
leukemia. Leukemia. 21:1116–1122. 2007.
|
|
10
|
Vonlanthen S, Heighway J, Altermatt HJ, et
al: The Bmi-1 oncoprotein is differentially expressed in non-small
cell lung cancer and correlates with INK4A-ARF locus expression. Br
J Cancer. 84:1372–1376. 2001.
|
|
11
|
Zhang FB, Sui LH and Xin T: Correlation of
Bmi-1 expression and telomerase activity in human ovarian cancer.
Br J Biomed Sci. 65:172–177. 2008.
|
|
12
|
Song LB, Li J, Liao WT, et al: The
polycomb group protein Bmi-1 represses the tumor suppressor PTEN
and induces epithelial-mesenchymal transition in human
nasopharyngeal epithelial cells. J Clin Invest. 119:3626–3636.
2009.
|
|
13
|
Guo BH, Feng Y, Zhang R, et al: Bmi-1
promotes invasion and metastasis, and its elevated expression is
correlated with an advanced stage of breast cancer. Mol Cancer.
10:102011.
|
|
14
|
Dhawan S, Tschen SI and Bhushan A: Bmi-1
regulates the Ink4a/Arf locus to control pancreatic beta-cell
proliferation. Genes Dev. 23:906–911. 2009.
|
|
15
|
Bruggeman SW, Hulsman D, Tanger E, et al:
Bmi1 controls tumor development in an Ink4a/Arf-independent manner
in a mouse model for glioma. Cancer Cell. 12:328–341. 2007.
|
|
16
|
Glinsky GV, Berezovska O and Glinskii AB:
Microarray analysis identifies a death-from-cancer signature
predicting therapy failure in patients with multiple types of
cancer. J Clin Invest. 115:1503–1521. 2005.
|
|
17
|
Häyry V, Tynninen O, Haapasalo HK, et al:
Stem cell protein BMI-1 is an independent marker for poor prognosis
in oligodendroglial tumours. Neuropathol Appl Neurobiol.
34:555–563. 2008.
|
|
18
|
Li J, Gong LY, Song LB, et al: Oncoprotein
Bmi-1 renders apoptotic resistance to glioma cells through
activation of the IKK-nuclear factor-kappaB pathway. Am J Pathol.
176:699–709. 2010.
|
|
19
|
Taylor LP: Diagnosis, treatment, and
prognosis of glioma: five new things. Neurology. 75:S28–S32.
2010.
|
|
20
|
Stupp R, Mason WP, van den Bent MJ, et al;
European Organisation for Research and Treatment of Cancer Brain
Tumor and Radiotherapy Groups; National Cancer Institute of Canada
Clinical Trials Group. Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.
|
|
21
|
Clarke J, Butowski N and Chang S: Recent
advances in therapy for glioblastoma. Arch Neurol. 67:279–283.
2010.
|
|
22
|
Stupp R, Hegi ME, Mason WP, et al;
European Organisation for Research and Treatment of Cancer Brain
Tumour and Radiation Oncology Groups; National Cancer Institute of
Canada Clinical Trials Group. Effects of radiotherapy with
concomitant and adjuvant temozolomide versus radiotherapy alone on
survival in glioblastoma in a randomised phase III study: 5-year
analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466.
2009.
|
|
23
|
Xie C, Wang H, Cheng H, Li J, Wang Z and
Yue W: RAD18 mediates resistance to ionizing radiation in human
glioma cells. Biochem Biophys Res Commun. 445:263–268. 2014.
|
|
24
|
Liu P, Huang Z, Chen Z, et al: Silver
nanoparticles: a novel radiation sensitizer for glioma? Nanoscale.
5:11829–11836. 2013.
|
|
25
|
Naidu MD, Mason JM, Pica RV, Fung H and
Peña LA: Radiation resistance in glioma cells determined by DNA
damage repair activity of Ape1/Ref-1. J Radiat Res. 51:393–404.
2010.
|
|
26
|
Jendrossek V: The intrinsic apoptosis
pathways as a target in anticancer therapy. Curr Pharm Biotechnol.
13:1426–1438. 2012.
|
|
27
|
Dewey WC, Ling CC and Meyn RE:
Radiation-induced apoptosis: relevance to radiotherapy. Int J
Radiat Oncol Biol Phys. 33:781–796. 1995.
|
|
28
|
Schmitt CA: Cellular senescence and cancer
treatment. Biochim Biophys Acta. 1775:5–20. 2007.
|
|
29
|
Roninson IB: Tumor cell senescence in
cancer treatment. Cancer Res. 63:2705–2715. 2003.
|
|
30
|
Li Y, Hu J, Guan F, et al: Copper induces
cellular senescence in human glioblastoma multiforme cells through
downregulation of Bmi-1. Oncol Rep. 29:1805–1810. 2013.
|
|
31
|
Jacobs JJ, Kieboom K, Marino S, DePinho RA
and van Lohuizen M: The oncogene and Polycomb-group gene Bmi-1
regulates cell proliferation and senescence through the ink4a
locus. Nature. 397:164–168. 1999.
|
|
32
|
Jiang L, Li J and Song L: Bmi-1, stem
cells and cancer. Acta Biochim Biophys Sin (Shanghai). 41:527–534.
2009.
|
|
33
|
Hara E, Smith R, Parry D, Tahara H, Stone
S and Peters G: Regulation of p16CDKN2 expression and its
implications for cell immortalization and senescence. Mol Cell
Biol. 16:859–867. 1996.
|
|
34
|
Molofsky AV, Pardal R, Iwashita T, Park
IK, Clarke MF and Morrison SJ: Bmi-1 dependence distinguishes
neural stem cell self-renewal from progenitor proliferation.
Nature. 425:962–967. 2003.
|
